On Tuesday, President Trump and Pfizer CEO Albert Bourla announced a major deal that stands to lower the prices of Pfizer pharmaceutical products for American consumers.
President Trump announced that Pfizer will be discounting drugs sold on the American market by 50 to 100 percent:
.@POTUS announces that @pfizer will provide some of their most popular medications to all Americans at heavily discounted prices of between 50%-100% off — and all new medications introduced to the U.S. market will be sold at the reduced Most Favored Nation cost 🔥 pic.twitter.com/YC0f8hzdAQ
— Rapid Response 47 (@RapidResponse47) September 30, 2025
The president said:
Pfizer has agreed to provide some of their most popular current medications to all consumers at heavily discounted prices. Anywhere between 50 and even 100 percent. And, that's off the price. And in some cases, even more than that. These drugs will be available for direct purchase online, at a website operated by the federal government. We're also announcing that, moving forward, all new medications introduced by Pfizer to the American market will be sold at the reduced, most-favored-nation cost. So we'll be paying, essentially, what other countries are paying.
Pfizer CEO Albert Bourla also spoke.
.@Pfizer CEO @AlbertBourla: The big winner of this deal clearly will be the American patient — there's no doubt about it. They are the ones that will see significant impact in their ability to buy medicines... We are ready to UNLEASH our investment portfolio in this country. 🇺🇸 https://t.co/SDmcFItFKf pic.twitter.com/G9V32nxZOD
— Rapid Response 47 (@RapidResponse47) September 30, 2025
Dr. Bourla said, in part:
The big winner of this deal, clearly, the American patient. There is no doubt about it. They are the ones that will see significant impact in their ability to buy medicines. But I would argue that it is not the only winner. If there is another winner here, it is American innovation, and the American economy.
Dr. Bourla described the deal as "reversing an unfair situation." Finally, he committed to moving product manufacturing into the United States. President Trump has, he said, agreed to a cessation of tariffs on Pfizer products for two years, to allow for the moves. Pfizer, he said, will be investing $70 billion in "the next few years" in manufacturing and research in the United States.
If it all works out, this is a significant deal.
Read More: MAHA: RFK Jr. Makes Good on COVID Vaccine Promise
Trump Drops Ultimatum to Big Pharma on COVID Vaccine Amid CDC Drama
The one item of concern might be, as President Trump describes, a website for the purchase of pharmaceuticals, run by the federal government. No details are yet available as to how this will work. Setting aside the constitutional concerns for a moment - the federal government has no constitutional authority to run a pharmaceutical outlet - it's a rather troubling notion. Any system set up under a Republican administration, no matter how well-run or effective it is at the onset, could be tampered with and messed up by a subsequent Democratic administration.
It would seem a better idea to let the private sector handle this part of the deal. The pricing agreements, meanwhile, are good news. The catch will be how long they last. Keep an eye on Pfizer's stock price over the next few days, as well. As of this writing, it's up about 5 percent.
The details of all this are, of course, yet to be worked out. Stay tuned.
Editor’s Note: Thanks to President Trump’s leadership and bold policies, America’s economy is back on track.
Help us continue to report on the president’s economic successes and combat the lies of the Democrats. Join RedState VIP and use promo code FIGHT to get 60% off your membership.
Join the conversation as a VIP Member